Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$32.24M$32.24Mderived−53.7% vs Q4 2024 Net Income$5.02M$5.02MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$24,100,000+9.4% Operating Incomederived$8,538,000+134.9% Operating Cash Flowderived$7,088,000+3,479.8% Free Cash Flowderived$7,077,000+3,809.9% Margins · derivedGross margin74.8%+43.1 pt vs Q4 2024
Operating margin26.5%+21.3 pt vs Q4 2024
Net margin15.6%+15.7 pt vs Q4 2024
ended Dec 31, 2025 · filed Mar 12, 2026 · 71 d after period end